Ensign Peak Advisors Inc Boosts Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Ensign Peak Advisors Inc boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 42.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,448 shares of the company's stock after acquiring an additional 15,036 shares during the period. Ensign Peak Advisors Inc owned 0.16% of Medpace worth $16,760,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Medpace during the fourth quarter valued at approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of Medpace during the 4th quarter valued at $31,000. Jones Financial Companies Lllp raised its stake in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC boosted its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Insiders Place Their Bets

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the transaction, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 20.30% of the company's stock.

Medpace Stock Performance

Medpace stock traded up $4.68 during mid-day trading on Thursday, reaching $296.41. 485,219 shares of the company were exchanged, compared to its average volume of 349,532. The business has a fifty day moving average of $305.47 and a 200 day moving average of $328.09. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77. The firm has a market cap of $8.52 billion, a P/E ratio of 23.47, a PEG ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The business had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same period in the prior year, the company posted $3.20 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Leerink Partners began coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Mizuho lowered their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Robert W. Baird reduced their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research report on Wednesday, April 23rd. Finally, TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and decreased their price target for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.